CFTR and Duchenne muscular dystrophy: The CRISPR/Cas9 system can also be used as a therapeutic technology for treating genetic disorders such as Duchenne muscular dystrophy (DMD) by correcting the dystrophin gene mutation (Long et al. 2014) or cystic fibrosis by repairing the mutation in the CFTR gene (Schwank et al. 2013).